company background image
REGN logo

Regeneron Pharmaceuticals NasdaqGS:REGN Stock Report

Last Price

US$674.27

Market Cap

US$71.0b

7D

-6.6%

1Y

-29.4%

Updated

13 Feb, 2025

Data

Company Financials +

Regeneron Pharmaceuticals, Inc.

NasdaqGS:REGN Stock Report

Market Cap: US$71.0b

REGN Stock Overview

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. More details

REGN fundamental analysis
Snowflake Score
Valuation5/6
Future Growth1/6
Past Performance4/6
Financial Health5/6
Dividends0/6

Community Narratives

Create a narrative

Narratives bring a range of perspectives from our community.

My Notes

Capture your thoughts, links and company narrative

Regeneron Pharmaceuticals, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Regeneron Pharmaceuticals
Historical stock prices
Current Share PriceUS$674.27
52 Week HighUS$1,211.20
52 Week LowUS$642.00
Beta0.079
1 Month Change-2.40%
3 Month Change-10.91%
1 Year Change-29.38%
3 Year Change7.59%
5 Year Change68.93%
Change since IPO3,091.81%

Recent News & Updates

Regeneron Q4 Earnings: Dividend And Dupixent Drive Solid Quarter - Eylea To Strike Back In 2025

Feb 04

Regeneron: Phase III Success In Skin Cancer For Libtayo

Jan 15

Recent updates

Regeneron Q4 Earnings: Dividend And Dupixent Drive Solid Quarter - Eylea To Strike Back In 2025

Feb 04

Regeneron: Phase III Success In Skin Cancer For Libtayo

Jan 15

Regeneron's Diversified Growth Makes It My Top Biopharma Pick For 2025

Jan 05

Is Regeneron Pharmaceuticals (NASDAQ:REGN) Using Too Much Debt?

Dec 13
Is Regeneron Pharmaceuticals (NASDAQ:REGN) Using Too Much Debt?

Regeneron: Recent Bear Run May Be Justified -- Pharma Faces A Testing 2025

Dec 06

Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Price Is Out Of Tune With Earnings

Nov 22
Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Price Is Out Of Tune With Earnings

Regeneron: The Biotech Stock To Buy Now

Nov 19

Regeneron: Buying A Promising Pipeline At A Fair Price (Rating Upgrade)

Nov 04

Amgen Biosimilar And EYLEA Patent Dispute: What It Means For Regeneron Investors

Sep 25

Is Regeneron Pharmaceuticals (NASDAQ:REGN) Using Too Much Debt?

Sep 09
Is Regeneron Pharmaceuticals (NASDAQ:REGN) Using Too Much Debt?

Regeneron Stock: Valuation Now Demands More Growth

Aug 26

Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Intrinsic Value Is Potentially 81% Above Its Share Price

Aug 22
Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Intrinsic Value Is Potentially 81% Above Its Share Price

Risks To Shareholder Returns Are Elevated At These Prices For Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Aug 04
Risks To Shareholder Returns Are Elevated At These Prices For Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Regeneron's Robust Pipeline And Financial Health Signal Continued Growth

Aug 02

Regeneron: Downgrading My Outlook To 'Hold' Ahead Of Q2 Earnings

Jul 11

Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) CEO Compensation Looks Acceptable To Us And Here's Why

Jun 08
Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) CEO Compensation Looks Acceptable To Us And Here's Why

These 4 Measures Indicate That Regeneron Pharmaceuticals (NASDAQ:REGN) Is Using Debt Reasonably Well

May 21
These 4 Measures Indicate That Regeneron Pharmaceuticals (NASDAQ:REGN) Is Using Debt Reasonably Well

Regeneron: Dissecting The First Quarter Results And Regulatory Setbacks

May 06

Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Popularity With Investors Is Under Threat From Overpricing

Apr 30
Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Popularity With Investors Is Under Threat From Overpricing

Is There An Opportunity With Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) 47% Undervaluation?

Apr 10
Is There An Opportunity With Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) 47% Undervaluation?

Shareholder Returns

REGNUS BiotechsUS Market
7D-6.6%-1.8%0.4%
1Y-29.4%-2.7%21.5%

Return vs Industry: REGN underperformed the US Biotechs industry which returned -2.7% over the past year.

Return vs Market: REGN underperformed the US Market which returned 21.5% over the past year.

Price Volatility

Is REGN's price volatile compared to industry and market?
REGN volatility
REGN Average Weekly Movement4.2%
Biotechs Industry Average Movement11.3%
Market Average Movement6.0%
10% most volatile stocks in US Market18.1%
10% least volatile stocks in US Market3.0%

Stable Share Price: REGN has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: REGN's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
198815,106Leonard Schleiferwww.regeneron.com

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia (HoFH) or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults.

Regeneron Pharmaceuticals, Inc. Fundamentals Summary

How do Regeneron Pharmaceuticals's earnings and revenue compare to its market cap?
REGN fundamental statistics
Market capUS$71.05b
Earnings (TTM)US$4.41b
Revenue (TTM)US$14.20b

16.4x

P/E Ratio

5.1x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
REGN income statement (TTM)
RevenueUS$14.20b
Cost of RevenueUS$7.10b
Gross ProfitUS$7.10b
Other ExpensesUS$2.69b
EarningsUS$4.41b

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)41.23
Gross Margin49.99%
Net Profit Margin31.07%
Debt/Equity Ratio6.8%

How did REGN perform over the long term?

See historical performance and comparison

Dividends

0.5%

Current Dividend Yield

n/a

Payout Ratio

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/13 05:14
End of Day Share Price 2025/02/13 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Regeneron Pharmaceuticals, Inc. is covered by 60 analysts. 24 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jasper HellwegArgus Research Company
Brian SkorneyBaird
Ishan MajumdarBaptista Research